2013 it submitted its New Medication Program to the U.

Anacor Pharmaceuticals submits tavaborole NDA to FDA for treatment of onychomycosis Anacor Pharmaceuticals announced today that in July 26, 2013 it submitted its New Medication Program to the U tablet cialis .S. Food and Drug Administration for tavaborole, its drug candidate for the topical treatment of onychomycosis. Onychomycosis is certainly a fungal an infection of the nail and nail that affects around 35 million people in the usa. Tavaborole is the first drug in our pipeline to reach this important milestone, and I'd prefer to acknowledge and thank the entire Anacor team for their hard work, persistence and dedication.

lilly cialis 5mg

1 effective date of the requirement brings association coverage beneath the same type of scrutiny that applies to other types of insurance policies in the individual and small-group markets. The rate review procedure, established under the health care legislation, requires insurers to give a detailed explanation of their reasons for raising premiums if they propose a rise of 10 % or even more . This article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family members Foundation. Kaiser Health News, an unbiased news service editorially, is a program of the Kaiser Family Foundation, a nonpartisan healthcare policy research corporation unaffiliated with Kaiser Permanente.. Analysis: How the health rules shakes out if Great Court overturns individual mandate Politico examines this critical concern and offers various scenarios of what may happen if the mandate is struck down.